[HTML][HTML] Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - nature.com
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - search.ebscohost.com
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - ui.adsabs.harvard.edu
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - zora.uzh.ch
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
[HTML][HTML] Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - ncbi.nlm.nih.gov
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - econpapers.repec.org
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - Nature …, 2023 - ideas.repec.org
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
B Calsina, E Piñeiro-Yáñez… - NATURE …, 2023 - flore.unifi.it
: The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are
unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein …
unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein …
[PDF][PDF] Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
B Calsina, E Piñeiro-Yáñez, ÁM Martínez-Montes… - 2023 - repository.ubn.ru.nl
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown,
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …
hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show …